摘要
Recent progress at the National Center for Nanoscience and Technology of China has enabled an extremely facile method to encapsulate irinotecan(CPT-11)into micelle-based nanoparticles(named as IH-NM).In preclinical study,compared with free CPT-11,IH-NM exhibited 1.56-fold higher maximum tolerance dose(MTD),-2.45-fold higher antitumor efficacy at 80%of MTD dosage,higher plasma exposure,and slower clearance from the plasma.The IH-NM technology received Clinical Trial Permission from the National Medical Products Administration(NMPA)of China on Mar 6,2019.The Phase I clinical trial is under preparation.
基金
supported by the"Strategic Priority Research Program"of the Chinese Academy of Sciences,Grant No.XDA09030301.
